

2017-2022 Global and Japan Hypolipidemic drugs Market Analysis Report

<https://marketpublishers.com/r/25E12BDB807EN.html>

Date: July 2017

Pages: 126

Price: US\$ 3,085.00 (Single User License)

ID: 25E12BDB807EN

Abstracts

The global Hypolipidemic drugs market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Hypolipidemic drugs development status and future trend in Japan, focuses on top players in Japan, also splits Hypolipidemic drugs by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players include

ABBOTT LABORATORIES LIMITED

Apotex Fermentation Inc.

BIOCON LIMITED IN Bangalore

Cadila Healthcare Limited

Chunghwa Chem Syn& Biotech Co., Ltd

CONCORD BIOTECH LIMITED Ahmedabad

Croda Europe Limited Leek

DAIICHI SANKYO CO., LTD. JP

Dr. Reddy's Laboratories Ltd

DSM Sinochem Pharma India

HIKAL LIMITED Bangalore

IPCA Laboratories Limited

Lek Pharmaceuticals d.d.
LUPIN LIMITED
Merck Sharp & Dohme B.V.
Moehs Iberica S.L. ES
MYLAN LABORATORIES LIMITED
Nexchem Pharmaceutical Co., Ltd. CN
OLON S.P.A. IT Rodano
Pfizer Inc.
Recordati S.p.A. IT Milano
SUN PHARMACEUTICAL LIMITED Mumbai
TEVA PHARMACEUTICAL Petach Tikva
Zhejiang Jiangbei Pharma Co. Ltd CN

Figure Global and Japan Market Size (Million USD) Comparison 2012-2022

Source: Annual Reports, Secondary Information, Press Releases, Expert Interviews and JP Research, July 2017

Geographically, this report splits the Japan market into six regions,

Tokyo
Yokohama
Osaka
Nagoya
Others

On the basis of product, the Hypolipidemic drugs market is primarily split into

by Product Cholic acid regulator

Cholestyramine
Colestipol
Divistyramine

by Product HMG-CoA reductase inhibitors

Simvastatin
Lovastatin
Pravastatin

Atorvastatin
Fluvastatin

by Product Adenylate cyclase inhibitors

Clofibrate
Fenofibrate
Lifibrate
Etofilline Clofibrate
Gfibrozil
Bezafibrate
Simfibrate

by Product Nicotinic acid drugs

Nicotinic Acid
Lnositol Hexanicotinate
Acipimox

by Product Others

Omega-3
Pantethine
Probucol
Elastase

Contents

1 HYPOLIPIDEMIC DRUGS OVERVIEW

- 1.1 Product Overview and Scope of Hypolipidemic drugs
- 1.2 Japan Hypolipidemic drugs Market by Applications/End Users
 - 1.2.1 Japan Hypolipidemic drugs Sales (MT) and Market Share Comparison by Applications (2012-2022)
 - 1.2.2 Hospital
 - 1.2.3 Pharmacy
 - 1.2.4 Clinic
 - 1.2.5 Cardiovasology
- 1.3 Japan Hypolipidemic drugs Market by Regions
 - 1.3.1 Japan Hypolipidemic drugs Market Size (Million USD) Comparison by Regions (2012-2022)
 - 1.3.2 Tokyo Hypolipidemic drugs Status and Prospect (2012-2022)
 - 1.3.3 Yokohama Hypolipidemic drugs Status and Prospect (2012-2022)
 - 1.3.4 Osaka Hypolipidemic drugs Status and Prospect (2012-2022)
 - 1.3.5 Nagoya Hypolipidemic drugs Status and Prospect (2012-2022)
 - 1.3.6 Others in Japan Hypolipidemic drugs Status and Prospect (2012-2022)
- 1.4 Japan Market Size (Sales and Revenue) of Hypolipidemic drugs (2012-2022)
 - 1.4.1 Japan Hypolipidemic drugs Sales (MT) and Growth Rate (%) (2012-2022)
 - 1.4.2 Japan Hypolipidemic drugs Revenue (Million USD) and Growth Rate (2012-2022)
- 1.5 Classification of Hypolipidemic drugs by Product Cholic acid regulator
 - 1.5.1 Japan Hypolipidemic drugs Sales (MT) Comparison by Types (2012-2022)
 - 1.5.2 Japan Hypolipidemic drugs Sales (MT) Market Share by Types in 2016
 - 1.5.3 Cholestyramine
 - 1.5.4 Colestipol
 - 1.5.5 Divistyramine
- 1.6 Classification of Hypolipidemic drugs by Product HMG-CoA reductase inhibitors
 - 1.6.1 Japan Hypolipidemic drugs Sales (MT) Comparison by Types (2012-2022)
 - 1.6.2 Japan Hypolipidemic drugs Sales (MT) Market Share by Types in 2016
 - 1.6.3 Simvastatin
 - 1.6.4 Lovastatin
 - 1.6.5 Pravastatin
 - 1.6.6 Atorvastatin
 - 1.6.7 Fluvastatin
- 1.7 Classification of Hypolipidemic drugs by Product Adenylate cyclase inhibitors

- 1.7.1 Japan Hypolipidemic drugs Sales (MT) Comparison by Types (2012-2022)
- 1.7.2 Japan Hypolipidemic drugs Sales (MT) Market Share by Types in 2016
- 1.7.3 Clofibrate
- 1.7.4 Fenofibrate
- 1.7.5 Lifibrate
- 1.7.6 Etofylline Clofibrate
- 1.7.7 Gfibrozil
- 1.7.8 Bezafibrate
- 1.7.9 Simfibrate
- 1.8 Classification of Hypolipidemic drugs by Product Nicotinic acid drugs
 - 1.8.1 Japan Hypolipidemic drugs Sales (MT) Comparison by Types (2012-2022)
 - 1.8.2 Japan Hypolipidemic drugs Sales (MT) Market Share by Types in 2016
 - 1.8.3 Nicotinic Acid
 - 1.8.4 Lnositol Hexanicotinate
 - 1.8.5 Acipimox
- 1.9 Classification of Hypolipidemic drugs by Product Others
 - 1.9.1 Japan Hypolipidemic drugs Sales (MT) Comparison by Types (2012-2022)
 - 1.9.2 Japan Hypolipidemic drugs Sales (MT) Market Share by Types in 2016
 - 1.9.3 Omega-3
 - 1.9.4 Pantethine
 - 1.9.5 Probuco
 - 1.9.6 Elastase

2 JAPAN HYPOLIPIDEMIC DRUGS MARKET COMPETITION BY PLAYERS/MANUFACTURERS

- 2.1 Japan Hypolipidemic drugs Sales and Market Share of Key Players/Manufacturers (2012-2017)
- 2.2 Japan Hypolipidemic drugs Revenue and Share by Players/Manufacturers (2012-2017)
- 2.3 Japan Hypolipidemic drugs Average Price (USD/Unit) by Players/Manufacturers (2012-2017)
- 2.4 Japan Hypolipidemic drugs Market Competitive Situation and Trends
 - 2.4.1 Japan Hypolipidemic drugs Market Concentration Rate
 - 2.4.2 Japan Hypolipidemic drugs Market Share of Top 3 and Top 5 Players/Manufacturers
 - 2.4.3 Mergers & Acquisitions, Expansion in Japan Market
- 2.5 Japan Players/Manufacturers Hypolipidemic drugs Manufacturing Base Distribution, Sales Area, Product Types

3 JAPAN HYPOLIPIDEMIC DRUGS SALES AND REVENUE BY REGIONS (2012-2017)

3.1 Japan Hypolipidemic drugs Sales (MT) and Market Share by Regions (2012-2017)

3.2 Japan Hypolipidemic drugs Revenue (Million USD) and Market Share by Regions (2012-2017)

3.3 Japan Hypolipidemic drugs Price (USD/Unit) by Regions (2012-2017)

4 JAPAN HYPOLIPIDEMIC DRUGS SALES AND REVENUE BY TYPE/ PRODUCT CATEGORY (2012-2017)

4.1 Japan Hypolipidemic drugs Sales (MT) and Market Share by Type (2012-2017)

4.2 Japan Hypolipidemic drugs Revenue (Million USD) and Market Share by Type (2012-2017)

4.3 Japan Hypolipidemic drugs Price (USD/Unit) by Type (2012-2017)

4.4 Japan Hypolipidemic drugs Sales Growth Rate (%) (%) by Type (2012-2017)

5 JAPAN HYPOLIPIDEMIC DRUGS SALES BY APPLICATION (2012-2017)

5.1 Japan Hypolipidemic drugs Sales (MT) and Market Share by Applications (2012-2017)

5.2 Japan Hypolipidemic drugs Sales Growth Rate (%) (%) by Applications (2012-2017)

5.3 Market Drivers and Opportunities

6 JAPAN HYPOLIPIDEMIC DRUGS PLAYERS/MANUFACTURERS PROFILES AND SALES DATA

6.1 ABBOTT LABORATORIES LIMITED

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Hypolipidemic drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Pharmacy Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Apotex Fermentation Inc.

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Hypolipidemic drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Clinic Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)

6.2.4 Main Business/Business Overview

6.3 BIOCON LIMITED IN Bangalore

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Hypolipidemic drugs Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Cardiovasology Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Cadila Healthcare Limited

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Hypolipidemic drugs Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Chunghwa Chem Syn& Biotech Co., Ltd

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Hypolipidemic drugs Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Chunghwa Chem Syn& Biotech Co., Ltd Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)

6.5.4 Main Business/Business Overview

6.6 CONCORD BIOTECH LIMITED Ahmedabad

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Hypolipidemic drugs Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 CONCORD BIOTECH LIMITED Ahmedabad Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Croda Europe Limited Leek

6.7.1 Company Basic Information, Manufacturing Base and Competitors

- 6.7.2 Hypolipidemic drugs Product Category, Application and Specification
 - 6.7.2.1 Product A
 - 6.7.2.2 Product B
- 6.7.3 Croda Europe Limited Leek Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)
- 6.7.4 Main Business/Business Overview
- 6.8 DAIICHI SANKYO CO., LTD. JP
 - 6.8.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.8.2 Hypolipidemic drugs Product Category, Application and Specification
 - 6.8.2.1 Product A
 - 6.8.2.2 Product B
 - 6.8.3 DAIICHI SANKYO CO., LTD. JP Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)
 - 6.8.4 Main Business/Business Overview
- 6.9 Dr. Reddy's Laboratories Ltd
 - 6.9.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.9.2 Hypolipidemic drugs Product Category, Application and Specification
 - 6.9.2.1 Product A
 - 6.9.2.2 Product B
 - 6.9.3 Dr. Reddy's Laboratories Ltd Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)
 - 6.9.4 Main Business/Business Overview
- 6.10 DSM Sinochem Pharma India
 - 6.10.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.10.2 Hypolipidemic drugs Product Category, Application and Specification
 - 6.10.2.1 Product A
 - 6.10.2.2 Product B
 - 6.10.3 DSM Sinochem Pharma India Hypolipidemic drugs Sales (MT), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)
 - 6.10.4 Main Business/Business Overview
- 6.11 HIKAL LIMITED Bangalore
- 6.12 IPCA Laboratories Limited
- 6.13 Lek Pharmaceuticals d.d.
- 6.14 LUPIN LIMITED
- 6.15 Merck Sharp & Dohme B.V.
- 6.16 Moehs Iberica S.L. ES
- 6.17 MYLAN LABORATORIES LIMITED
- 6.18 Nexchem Pharmaceutical Co., Ltd. CN
- 6.19 OLON S.P.A. IT Rodano

- 6.20 Pfizer Inc.
- 6.21 Recordati S.p.A. IT Milano
- 6.22 SUN PHARMACEUTICAL LIMITED Mumbai
- 6.23 TEVA PHARMACEUTICAL Petach Tikva
- 6.24 Zhejiang Jiangbei Pharma Co. Ltd CN

7 HYPOLIPIDEMIC DRUGS MANUFACTURING COST ANALYSIS

- 7.1 Hypolipidemic drugs Key Raw Materials Analysis
 - 7.1.1 Key Raw Materials
 - 7.1.2 Price Trend of Key Raw Materials
 - 7.1.3 Key Suppliers of Raw Materials
 - 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
 - 7.2.1 Raw Materials
 - 7.2.2 Labor Cost
 - 7.2.3 Manufacturing Expenses
- 7.3 Manufacturing Process Analysis of Hypolipidemic drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 8.1 Hypolipidemic drugs Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Hypolipidemic drugs Major Players/Manufacturers in 2015
- 8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 9.1 Marketing Channel
 - 9.1.1 Direct Marketing
 - 9.1.2 Indirect Marketing
 - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
 - 9.2.1 Pricing Strategy
 - 9.2.2 Brand Strategy
 - 9.2.3 Target Client
- 9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 JAPAN HYPOLIPIDEMIC DRUGS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

11.1 Japan Hypolipidemic drugs Sales (MT), Revenue (Million USD) Forecast (2017-2022)

11.2 Japan Hypolipidemic drugs Sales (MT) Forecast by Type (2017-2022)

11.3 Japan Hypolipidemic drugs Sales (MT) Forecast by Application (2017-2022)

11.4 Japan Hypolipidemic drugs Sales (MT) Forecast by Regions (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

I would like to order

Product name: 2017-2022 Global and Japan Hypolipidemic drugs Market Analysis Report

Product link: <https://marketpublishers.com/r/25E12BDB807EN.html>

Price: US\$ 3,085.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/25E12BDB807EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970